Elaidic acid

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

Senescence-associated beta-galactosidase

upin mouse cells1

1 study

Elaidic acid increases senescence-associated beta-galactosidase in mouse cells.
“Upon DNA damage, EA enhanced senescence-associated β-galactosidase activity and expressions of IL-1α/6/8 through the IL-1R-transforming growth factor-β-activated kinase 1 (TAK1)-nuclear factor (NF)-κB axis”
Cellsupon DNA damage
Elaidic acid drives cellular senescence and inflammation via lipid raft-mediated IL-1R signaling
iScience6 Aug 2025

More on Senescence-associated beta-galactosidase

Cellular senescence

upin mouse cells1

1 study

Elaidic acid increases cellular senescence in mouse cells.
“Here, we show that in response to DNA damage, elaidic acid (EA), a most common TFA, amplifies interleukin-1 receptor (IL-1R) signaling, leading to the promotion of cellular senescence and senescence-associated secretory phenotype (SASP).”
Cellsin response to DNA damage
Elaidic acid drives cellular senescence and inflammation via lipid raft-mediated IL-1R signaling
iScience6 Aug 2025